Navigation Links
Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Date:9/24/2007

FRAMINGHAM, Mass., Sept. 24 /PRNewswire/ -- Iodine has been used as an antimicrobial for the last century. Much has been written about molecular iodine yet many women suffering from Fibrocystic Breast Disease (FBD) are unaware that studies being conducted may soon yield an effective nonhormonal treatment.

While there are several breast cancer drugs on the market, all available hormonal therapies have significant adverse events. In contrast, IoGen is a nonhormonal treatment that allows for safe long-term use with little or no side effects.

"Current research provides substantive support for the initiation of human clinical studies on the use of molecular iodine as a treatment for breast disease," stated Paul Desjourdy, President and CEO, Symbollon Pharmaceuticals, Inc. "The possibility that IoGen may be used as a treatment for breast cancer makes it all the more important that we expedite the commercialization time line."

The Company believes IoGen has the ability to eliminate excess cell growth in female reproductive tissue, including the breast, ovaries and uterus. Other indications for IoGen include the treatment or prevention of endometriosis, ovarian cysts, and premenopausal breast cancer.

Symbollon Pharmaceuticals, Inc. is now in FDA Phase III clinical trials for the evaluation of IoGen (I2) for pain/tenderness associated with FBD and with potential to treat female reproductive organ cancers.

The importance of (I2) in the treatments for mammary gland dysfunctions has been corroborated in human and animal models.

Seaweeds, containing high quantities of iodine in several chemical forms including (I2), have been associated with low incidences of benign and malignant breast disease in Asian women.

Past studies by independent researchers have supported the possible effectiveness of molecular iodine (I2) as a treatment for breast cancer.

-- Researchers at Drexel University College of Medicine found that

m
'/>"/>

SOURCE Symbollon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
8. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
9. Genetic Analysis Systems Enter the Clinical Mainstream
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced ... in,combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) ... hepatitis C,virus (HCV) genotype 1. R7128 is a ... inhibitor of HCV that is being developed,through Pharmasset,s ...
... EDMONTON, Alberta, Oct. 2 Medical Services,International Inc. (Pink ... its VScan Dengue Fever Kit is increasing. Dengue Fever ... of the worst,outbreaks in decades causing agonizing joint pain ... so far this year. This year so far ...
Cached Medicine Technology:Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 2Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 3Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 4Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 5Demand for VScan Dengue Fever Test Kits Increases 2
(Date:5/25/2013)... On May 25, Voices Against Brain Cancer, ... comments on a new study by the Max Planck ... plasma into brain cancer treatment may help when dealing ... Science Daily article, physicists from the Max Planck ... the “synergistic effect of cold atmospheric plasma -- a ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 For ... than finals week. Increasingly, they are turning to ... awake and study. For more on this, go ... drug treatment facility, warns that students who pick ... are at risk for developing a physical and ...
(Date:5/25/2013)... Richmond, Virginia (PRWEB) May 25, 2013 ... bracelet that relieves pain in seconds for arthritis, tendinitis ... innovator in alternative pain relief products announced a ... seconds. The magnetic bracelet for pain relief is demonstrated ... for pain uses 5400 Gauss magnets and has customers ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... to relieve stress, a common cause of heart ... ... us think,of love and Valentine,s Day. This February, which also is National Heart,Awareness ... your heart. A healthy heart can be attained in a variety,of ways that ...
... PORTLAND, Ore. An Oregon Health & Science University Cancer ... the ability to predict if a mans prostate cancer is ... In order to make this discovery, researchers examined prostate cancer ... cancer patients. The researchers found that men whose tumors showed ...
... course of the presidential nomination campaign, some candidates health ... the phrase socialized medicine has been used to attack ... poll by the Harvard Opinion Research Program at the ... finds that Americans are split on whether a socialized ...
... National Board, KNOXVILLE, Tenn., Feb. 14 ... of Stacy Goldsholl, MD, as an,officer of its ... Medicine, is serving her second consecutive term as ... the premier medical society that,represents hospitalists. Hospital medicine ...
... (Nasdaq: DATA ), a technology company focused ... today reported that it will be,presenting at the ... at the Ritz Carlton in Laguna Niguel, California, ... on Wednesday afternoon,February 20th at 2:30 P.M., Pacific ...
... researchers from Europe and North America were given important ... national boundaries at a two-day training course in Croydon, ... Foundation as part of its Pan-European Clinical Trials (ECT) ... trials with a specific focus on the Euramos trial ...
Cached Medicine News:Health News:Healthy Heart, Healthy Home 2Health News:OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Stacy Goldsholl, MD, Re-elected to Board of Society of Hospital Medicine 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 3Health News:ESF's EMRC strengthens training course on clinical trials management 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: